Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aadi Bioscience (AADI)
NASDAQ:AADI
Holding AADI?
Track your performance easily
Earnings Data
Report Date
Mar 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.21Last Year’s EPS
-$0.6Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: 70.35%
|Next Earnings Date:Mar 13, 2025
Earnings Call Sentiment|Positive
Aadi Bioscience showcased strong growth in FYARRO sales and promising developments in clinical trials, particularly PRECISION1 and endometrial cancer studies. Financial stability and effective cost management were highlighted, despite the challenges posed by the rare PEComa market and a net loss for the quarter.Company Guidance
During the Aadi Bioscience Q2 2024 earnings call, the company provided comprehensive guidance on their current and future initiatives, highlighting key metrics and strategic plans. The call detailed the performance of FYARRO, which achieved $6.2 million in product sales for the quarter, marking a 15% increase over Q1 and bringing cumulative sales to $51.1 million since its launch. The PRECISION1 trial, which is focused on solid tumors with TSC1 or TSC2 inactivating alterations, has fully enrolled 120 patients and is projected to complete by the end of the year, with an interim readout expected in Q3 2024. The company anticipates a cash runway extending into Q4 2025. Moreover, research and development expenses stood at $13.1 million, while selling, general, and administrative expenses were $7.9 million, contributing to a net loss of $14.6 million for the quarter. Aadi Bioscience remains optimistic about the commercial potential of nab-Sirolimus, targeting a significant market opportunity estimated between $300 million and $600 million in the U.S. alone.FYARRO Sales Growth
FYARRO product sales reached $6.2 million for the second quarter, a 15% increase over Q1, with a 14% increase in the number of ordering accounts compared to the first quarter.
PRECISION1 Trial Progress
The PRECISION1 trial is fully enrolled with 120 patients. The next interim readout is expected in Q3 2024, which will evaluate the primary endpoint of independently assessed overall response rate.
Financial Stability
Aadi Bioscience ended Q2 2024 with $78.6 million in cash, cash equivalents, and short-term investments, providing a cash runway into Q4 2025.
Cost Management
Selling, general, and administrative expenses decreased to $7.9 million from $11.8 million in the same period in 2023, driven by reduced commercial, marketing, and personnel expenses.
Endometrial Cancer Trial
The trial for advanced or recurrent endometrial type endometrial cancer is enrolling well, with the first cohort completed and the second underway.
---
AADI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AADI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $1.99 | $2.12 | +6.53% |
| Aug 07, 2024 | $1.40 | $1.35 | -3.57% |
| May 08, 2024 | $2.11 | $1.84 | -12.80% |
| Mar 13, 2024 | $1.94 | $2.16 | +11.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Aadi Bioscience (AADI) report earnings?
Aadi Bioscience (AADI) is schdueled to report earning on Mar 13, 2025, TBA Not Confirmed.
What is Aadi Bioscience (AADI) earnings time?
Aadi Bioscience (AADI) earnings time is at Mar 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AADI EPS forecast?
AADI EPS forecast for the fiscal quarter 2024 (Q4) is -$0.21.
---